Oscar Health Q3 2025 earnings were not about optics but about recalibrating to shifting ACA individual market dynamics.
The company entered 2025 expecting a normalized ACA environment. Instead, it encountered a market where morbidity shifted upward after pricing was complete, Medicaid redeterminations pushed higher-risk members into the exchange pool, and program integrity efforts introduced mid-cycle disruption.
The result was a quarter that, on the surface, showed widening losses and a higher medical loss ratio. But underneath the noise was something more important: management is pricing 2026 as a structural reset year.
The central question for investors is not whether Q3 was messy. It was. The real question is whether Oscar has used 2025 to reposition its book, pricing discipline, and cost structure to restore margin durability next year.
Table of Contents
Earnings Snapshot: Oscar Health Q3 2025
Oscar Health reported $3.0 billion in revenue, up 23% year over year, with membership rising 28% to 2.1 million lives.
The medical loss ratio increased to 88.5% due primarily to a $130 million rise in risk adjustment payable.
Loss from operations totaled $129 million, and adjusted EBITDA was negative $101 million.
Oscar Health’s full Q3 2025 financial results are available in the Oscar Health Q3 2025 earnings press release.
Oscar Health Q3 2025 Earnings: Growth Intact, Margins Reset
“Oscar Health membership growth remains structurally strong. The margin picture does not.
Oscar reported $3 billion in revenue in the quarter, up 23% year-over-year, highlighting Oscar Health revenue growth 2025 alongside a 28% increase in membership to 2.1 million lives.
Those numbers, in isolation, suggest a company still capturing share in the individual market. But higher market morbidity and risk adjustment true-ups overwhelmed operating leverage.
The core financial picture can be summarized cleanly:
| Metric | Q3 2025 |
|---|---|
| Revenue | $3.0 billion |
| Revenue Growth | +23% YoY |
| Membership | 2.1 million |
| Membership Growth | +28% YoY |
| Medical Loss Ratio | 88.5% |
| SG&A Ratio | 17.5% |
| Loss from Operations | $129 million |
| Adjusted EBITDA Loss | $101 million |
| Net Loss | $137 million |
The 88.5% Oscar Health medical loss ratio increased by roughly 380 basis points year over year. The primary driver was a $130 million increase in risk adjustment payable, underscoring the risk adjustment payable analysis investors are now focused on, partially offset by $84 million in favorable prior period development.
The loss from operations widened to $129 million. Adjusted EBITDA was negative $101 million. Net loss was $137 million.
That is the headline.
The interpretation requires nuance.
Management emphasized that, stripping out the unexpected morbidity shift, the underlying MLR would have been consistent with original expectations in the low 81% range. In other words, the operational engine is behaving largely as modeled; the market environment shifted around it.
As CFO Richard Blackley put it:
“When I look at the core performance of the company this year and I strip out kind of what happened with the impacts of market morbidity shifting higher this year… the underlying MLR is pretty consistent with the guidance that we gave at the beginning of the year in the low 81% range.”
The distinction matters. Oscar is not arguing that execution deteriorated. It argues that pricing assumptions were overtaken by structural shifts in the risk pool.
Whether investors accept that framing depends on what happens next.
Market Morbidity: The Risk Adjustment Shock
The defining variable of 2025 has been higher-than-expected market morbidity.
Risk adjustment data from Wakely Consulting Group showed an additional 1.5 to 2 percentage point increase across several markets in Q3, reflecting both Medicaid redetermination flows and program integrity effects. Importantly, that data captured claims through July and therefore did not include the full effect of third-quarter churn from “failure to respond” rechecks or dual enrollment cleanup.
Oscar increased its 2025 risk adjustment payable by $130 million in Q3 alone, a direct consequence of the CMS risk adjustment program’s redistribution of funds based on relative member morbidity across issuers. That adjustment meaningfully lifted the reported MLR and reinforced management’s view that 2025 is a reset year for the ACA marketplace.
There are three structural forces at work:
- Medicaid Redeterminations: As Medicaid coverage unwound, higher-acuity lives migrated into ACA plans.
- Program Integrity Actions: Mid-year efforts altered the composition of the enrolled population.
- Subsidy Expiration Risk: The looming expiration of enhanced premium tax credits could lead to enrollment contraction and adverse selection.
Oscar’s posture is not defensive; it is anticipatory. The company has priced 2026 assuming both elevated morbidity and the expiration of subsidies.
That is a critical strategic choice.
What Q2 Promised — and What Q3 Delivered
The second quarter call was not just a warning about market volatility. It was a roadmap. Management laid out specific expectations about utilization normalization, expense discipline, capital resilience, and pricing response. Q3 now allows investors to separate foresight from aspiration.
Several themes from Q2 were directly tested in Q3.
First: utilization moderation.
In Q2, management argued that utilization had already begun to normalize sequentially, particularly outside inpatient services. That claim was critical because it framed the margin pressure as timing-driven rather than structural.
Q3 validated the thesis. While reported MLR rose due to risk adjustment accruals, management reiterated that underlying utilization trends remained consistent with original expectations. Favorable prior-period development of $84 million in Q3 reinforces the view that claims behavior did not spiral further as feared.
Utilization did not fix margins — but it also did not deteriorate further. That distinction matters.
Second: SG&A discipline.
In Q2, Oscar committed to meaningful cost actions, explicitly guiding toward approximately $60 million in administrative cost removal heading into 2026 and an improved full-year SG&A ratio.
Q3 delivered measurable progress. The SG&A ratio improved to 17.5%, down 150 basis points year-over-year and within the tightened guidance range reaffirmed in the prior quarter. This confirms that cost actions were not merely announced — they were executed.
More importantly, the cost story remains structural rather than cyclical. Fixed-cost leverage, exchange fee reductions, and AI-driven workflow automation are all evident in the numbers.
Third: capital resilience.
In Q2, management emphasized balance sheet strength as a buffer against volatility, noting excess subsidiary capital and flexibility to absorb operating losses without distress.
Q3 reinforced that posture. Cash and investments remained robust at $4.8 billion, and the company proactively refinanced its capital structure through a convertible issuance that extended the runway rather than plugging holes. This was not reactive financing. It was opportunistic.
The capital plan articulated in Q2 held under pressure.
Where Q2 expectations remain unproven.
Two areas remain forward-looking rather than validated.
First, management’s confidence that the market morbidity shock largely occurred in early 2025 has not yet been fully tested across a complete risk adjustment cycle. Q3 showed no new deterioration, but it did not yet prove stabilization.
Second, the belief that aggressive 2026 pricing will translate into profitable share gains remains theoretical. Q3 confirms preparation, not outcome.
That distinction is critical. Q3 validated execution discipline — not the payoff.
The takeaway: the Q2 call was not a misdirection exercise. The operational claims made then largely held up under Q3 scrutiny. What remains unresolved is not whether Oscar executed its reset plan, but whether the market environment will reward it in 2026.
Pricing 2026: Defensive Assumptions, Offensive Intent
Oscar resubmitted 2026 rate filings covering nearly 99% of current membership with a weighted average rate increase of approximately 28%.
That number appears high in isolation. It is slightly above the roughly 26% national average cited by Kaiser research, and it reflects a combination of:
- Elevated core trend
- Higher observed 2025 morbidity
- Expiration of enhanced premium tax credits
- Program integrity impacts
Management has explicitly stated that it priced as if subsidies disappear and market contraction reaches the higher end of its internal estimate.
The company believes the ACA market could shrink by 20% to 30% absent a subsidy extension. It is priced toward the higher end of that range.
The strategic logic is straightforward: overprice for resilience, then compete for share if others retreat.
CEO Mark Bertolini framed the share opportunity this way:
“Taking market share really means taking advantage of people who priced way out of the market… we’re pricing off of the underlying cost of the network because we get covered on the risk adjustment side.”
This is not a land-grab strategy. Management repeatedly described the market as rational. The bet is that disciplined pricing, combined with narrow network underwriting, can capture profitable share as less efficient competitors either exit or overshoot on price.
If the market contracts but Oscar captures incremental share within a disciplined risk framework, margin recovery becomes plausible.
If the market contracts and morbidity worsens further, pricing resilience will be tested.
SG&A: Structural Leverage and AI as Cost Tooling
One of the brighter structural elements in Oscar’s model has been operating leverage in administrative costs.
The Q3 SG&A ratio improved 150 basis points year-over-year to 17.5%. Full-year guidance remains 17.1% to 17.6%.
That improvement was driven by:
- Fixed cost leverage
- Lower exchange fee rates
- Variable cost discipline
Management also indicated that approximately $60 million in administrative costs have been removed heading into 2026.
The longer-term target of a 16% SG&A ratio by 2027 remains intact.
Importantly, Oscar’s AI narrative is not framed as a consumer acquisition story. It is framed as cost structure optimization.
The company now has more than two dozen AI models operating internally and has launched its first “agentic” model, Oswell, integrated into its tech stack. Management emphasized backend efficiency gains and workflow automation rather than top-line acceleration.
As Bertolini explained:
“We actually believe we have more room in our SG&A as we go forward… we have a lot of really good opportunity with AI to streamline our operating costs.”
This matters because Oscar’s path back to profitability requires two things simultaneously:
- A normalized MLR in the mid-80s.
- Continued administrative leverage toward mid-teens percentages.
Without both, 2026 profitability becomes harder to deliver.
Membership Dynamics: Early Signals, No Commitments
ACA open enrollment trends 2026 were only five days underway at the time of the call, but management reported higher-than-expected early activity.
That said, they were careful not to extrapolate.
The company invested heavily in the broker channel, ACA enrollment education, and plan mapping ahead of enrollment, particularly for members at risk of losing subsidies. Bronze and gold plans were priced to account for potential subsidy losses, and brokers were trained to guide members accordingly.
Oscar also benefited from auto-mapping when certain competitors exited markets.
The key dynamic to monitor is not early enrollment velocity. It is a composition.
If enhanced premium tax credits expiration triggers a 20–30% contraction, the risk pool may skew differently. Oscar believes it has priced for that possibility, but the proof will be visible in the 2026 MLR performance.
Capital Position: Strengthened for Volatility
Oscar ended Q3 with approximately $4.8 billion in cash and investments, including $541 million at the parent level. Insurance subsidiaries held $1.2 billion of capital and surplus, including $564 million of excess capital.
During the quarter, the company issued $410 million of convertible notes due 2030, generating $360 million in net proceeds after a capped call transaction that raised the effective conversion price to $37.46, as detailed in the Oscar Health 10-Q filed with the SEC.
It also entered into an agreement to redeem the majority of its $305 million in outstanding convertible senior notes for shares.
The capital posture suggests management is building optionality rather than reacting to distress. The balance sheet appears capable of absorbing another year of operating losses if necessary, though the stated objective is profitability in 2026.
Liquidity is not the immediate constraint. Execution is.
Narrow Networks and Underwriting Philosophy
One subtle but important theme in the call was Oscar’s emphasis on underwriting provider networks rather than individual members.
Because of the ACA risk adjustment mechanism, management argues that underwriting the network is more impactful than selectively underwriting individual risks.
Oscar’s narrow network cost advantage is central to its cost structure. It allows differentiated pricing compared to competitors, leveraging broader commercial networks.
The company did not explicitly quantify its cost advantage, but management suggested that its curated network design underpins both competitive pricing and durable margins.
This becomes especially relevant if the market contracts. A smaller market with more disciplined competitors rewards those with structurally lower cost-to-serve models.
Oscar is betting it is one of them.
The Central Question: Is 2025 a One-Year Reset or Structural Deterioration?
Investors must separate cyclical volatility from structural erosion.
The evidence from Q3 suggests:
- Revenue growth remains strong.
- Membership growth remains strong.
- Administrative leverage is improving.
- Underlying utilization trends are moderating.
- Core trend assumptions for 2026 are conservative.
What disrupted profitability was a step-change in morbidity that occurred after pricing.
Management has responded with a health insurer margin expansion strategy by:
- Pricing 2026 aggressively for higher morbidity.
- Assuming subsidy expiration.
- Removing $60 million in administrative costs.
- Strengthening capital flexibility.
If those assumptions prove overly conservative, margin expansion in 2026 could exceed expectations. If morbidity continues to worsen or pricing competition intensifies, the reset may be extended.
The company’s guidance for 2025 remains:
| Metric | 2025 Guidance |
|---|---|
| Revenue | $12.0B – $12.2B |
| Medical Loss Ratio | 86.0% – 87.0% |
| SG&A Ratio | 17.1% – 17.6% |
| Loss from Operations | $200M – $300M |
Revenue is expected toward the low end due to risk adjustment impacts. Operating loss guidance remains unchanged, suggesting offsetting claims development and cost efficiencies.
The signal embedded in that reaffirmation is confidence.
The market must decide whether that confidence is justified.
What the Earnings Show
Oscar Health Q3 2025 earnings indicate that growth in revenue and membership remains intact, but profitability was pressured by elevated market morbidity and higher risk adjustment accruals.
Management responded by aggressively pricing 2026 for potential ACA market contraction while continuing administrative cost reductions and capital strengthening.
Reframing the Narrative
Oscar Health is not trying to win 2025.
It is trying to survive intact and emerge structurally stronger in 2026.
The ACA marketplace is volatile by design. Policy uncertainty, risk adjustment mechanics, and subsidy shifts create a system where pricing mistakes can cascade. The company is arguing that 2025 exposed systemic fragility across the market and that disciplined operators will benefit as weaker participants retrench.
This quarter was not about earnings momentum but about stress-testing the model within evolving ACA individual market dynamics.
If 2026 delivers normalized morbidity within the bounds of Oscar’s 28% rate increase and administrative leverage continues toward mid-teens SG&A, the return to profitability becomes plausible and potentially durable.
If the reset proves incomplete, investors will question whether ACA volatility structurally caps margin expansion.
The analytical frame of Oscar Health Q3 2025 earnings remains clear: the company has priced for contraction and volatility. It believes it can grow its share profitably in a shrinking market.
The next twelve months will determine whether that confidence reflects a structural advantage—or just disciplined optimism.
To see the assumptions that shaped this reset year, revisit Oscar Health Q2 2025 earnings breakdown.
Quarter at a Glance
The third quarter reflected stable operational execution alongside external market disruption.
Utilization trends moderated sequentially, SG&A leverage improved, and capital flexibility increased.
Margin deterioration stemmed primarily from risk adjustment adjustments rather than structural breakdown in cost discipline.
Key Takeaways
Oscar Health Q3 2025 earnings reflect a pricing reset rather than an operational breakdown. Revenue and membership growth remained strong despite margin pressure.
Higher medical loss ratios were driven primarily by changes in risk adjustment and elevated morbidity, not by structural cost deterioration.
Management priced 2026 assuming both elevated risk and subsidy expiration, signaling defensive positioning with the potential for share gains.
Administrative leverage continues to improve, with cost reductions and AI-driven efficiencies supporting the long-term SG&A target.
Capital flexibility appears sufficient to absorb volatility, shifting the focus toward execution and pricing accuracy in 2026.
This analysis establishes the baseline ahead of Oscar Health’s Q4 2025 earnings, during which pricing execution and enrollment composition will come into sharper focus.
Questions Investors Are Asking
Why did the medical loss ratio increase so sharply?
The increase was largely driven by a $130 million rise in risk adjustment payable, reflecting higher-than-expected market morbidity after pricing was finalized. Management indicated the underlying utilization trends were closer to original expectations.
Is revenue growth masking deeper structural issues?
Revenue and membership growth remain strong, up 23% and 28% respectively. The disruption appears tied to morbidity shifts rather than demand weakness or competitive erosion.
How aggressive is the 2026 pricing strategy?
Oscar implemented a weighted average rate increase of approximately 28%, pricing toward the higher end of projected market contraction and assuming subsidy expiration.
What happens if subsidies are extended?
Management priced assuming expiration. If subsidies remain, enrollment contraction may be less severe than modeled, potentially improving margin outcomes.
Is the balance sheet strong enough to handle volatility?
With $4.8 billion in cash and investments and excess subsidiary capital, liquidity does not appear to be an immediate constraint.
How important is SG&A leverage to profitability?
Administrative cost discipline is central to the 2026 profitability path. Continued improvement toward mid-teens SG&A ratios is required alongside normalized MLR performance.
Get More Earnings Breakdowns and Investor Insights
This site is built for investors who want straightforward, in-depth breakdowns of earnings calls—without the jargon. Whether you follow SoFi, Amazon, Dutch Bros, or other high-growth names, we’ve got you covered. Explore our latest posts and stay tuned—new recaps and insights drop regularly.
Check out our dedicated Oscar Health page for all the latest posts and deep dives, from earnings breakdowns to ongoing coverage.
Written by Bryan Smith, creator of Straight From the Call.
I break down earnings calls so you don’t have to. Clear takeaways, no fluff — just the stuff investors care about.
This post is for informational and educational purposes only. It does not constitute financial, investment, or legal advice. Always do your own research or consult a licensed professional before making financial decisions. For the full policy, see our Not Investment Advice & Disclosure Statement.